Results 11 to 20 of about 6,313 (203)

Glargine and degludec: Solution behaviour of higher dose synthetic insulins [PDF]

Scientific Reports, 2017
Single, double and triple doses of the synthetic insulins glargine and degludec currently used in patient therapy are characterised using macromolecular hydrodynamic techniques (dynamic light scattering and analytical ultracentrifugation) in an attempt ...
Gary G. Adams, Qushmua Alzahrani, Shahwar I. Jiwani, Andrew Meal, Paul S. Morgan, Frank Coffey, Samil Kok, Arthur J. Rowe, Stephen E. Harding, Naomi Chayen, Richard B. Gillis   +10 more
doaj   +3 more sources

A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks. DUAL VIII, a randomized trial designed to resemble clinical practice [PDF]

, 2020
This report presents the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as initial injectable therapy at 26 weeks in the 104-week DUAL VIII durability trial (NCT02501161). Participants (N =
Aroda, V. R., Bardtrum, L., Dagdelen, S., Halladin, N., Haluzik, M., Orsy, P., Rodriguez, M., Sesti, G.   +7 more
core   +1 more source

DUAL I China:在一项对未服用口服降糖药物的中国2型糖尿病患者进行的随机试验中, IDegLira与其单独成分相比改善了血糖控制

Journal of Diabetes, 2022
Background DUAL I China, one of the DUAL trials, assessed efficacy/safety of insulin degludec/liraglutide (IDegLira) in Chinese adults with type 2 diabetes (T2D) not controlled by oral antidiabetic drugs (OADs).
Weiqing Wang, Bue F. Ross Agner, Bin Luo, Lei Liu, Ming Liu, Yongde Peng, Shen Qu, Karolina Amelia Stachlewska, Guixia Wang, Guoyue Yuan, Qiu Zhang, Guang Ning   +11 more
doaj   +1 more source

Basal insulin titration algorithms in patients with type 2 diabetes: the simplest is the best (?)

Mìžnarodnij Endokrinologìčnij Žurnal, 2023
Basal insulin is the first and main component of insulin therapy in patients with type 2 diabetes mellitus (T2DM). Based on the shortcomings of human NPH insulin and the advantages provi­ded by long-acting basal insulin analogues, they are recommended ...
V.I. Katerenchuk
doaj   +1 more source

Comparison of efficacy of detemir and degludec insulin in the management of children and adolescents with type 1 diabetes

Journal of Diabetology, 2022
Aims and Objectives: Despite the advantages offered by current basal analogs, the management of type 1 diabetes (T1D) in children and adolescents is a great challenge till now.
Bedowra Zabeen, Bulbul Ahmed, Nasreen Islam, Samin Tayyeb, Jebun Nahar, Kishwar Azad   +5 more
doaj   +1 more source

Insulin Degludec/Liraglutide [PDF]

Hospital Pharmacy, 2017
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
openaire   +2 more sources

Spotlight commentary-Insulin therapy: Future directions. [PDF]

Br J Clin Pharmacol
British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 351-353, February 2026.
Deškin A, Cifrek K, Stričak LM, Hladnik A, Barilar JO.   +4 more
europepmc   +2 more sources

The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): a short‐term cost‐effectiveness analysis in the UK setting [PDF]

, 2018
Aim: To evaluate the cost‐effectiveness of IDegLira versus basal‐bolus therapy (BBT) with insulin glargine U100 plus up to 4 times daily insulin aspart for the management of type 2 diabetes in the UK.
ADVANCE Collaborative Group, American Diabetes Association Consensus Panel, Anderson, Bagust, Bagust, Billings, Blak, Boye, Chubb, Control Group, Currie, Donnelly, Duckworth, Evans, Forst, Gaede, Gaede, Giugliano, Grandy, Hammer, Holman, Hunt, Hunt, Hunt, Inzucchi, Ismail-Beigi, Johnston, Lee, Matza, McCabe, Meneghini, Mezquita-Raya, National Institute for Health and Care Excellence (NICE), Nauck, Parekh, Peyrot, Peyrot, Ridderstråle, Russell-Jones, Shi, Stettler, The Forum for Injection Technique (FIT), TREND-UK, UK Prospective Diabetes Study (UKPDS) Group, UK Prospective Diabetes Study (UKPDS) Group, Walz, Wang, Wild   +47 more
core   +1 more source

Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources [PDF]

, 2016
Aims: To assess resource utilization associated with severe hypoglycaemia across three insulin regimens in a large phase 3a clinical programme involving people with Type 1 diabetes treated with basal–bolus insulin, people with Type 2 diabetes treated ...
Akram, Brod, Budnitz, Dailey, Davies, Donnelly, Evans, Foos, Frier, Frier, Fulcher, Garber, Geller, Gough, Graveling, Greco, Hammer, Harris, Harris, Heller, Heller, Hirsch, International Conference on Harmonisation, Kaneko, Kristensen, Lammert, Leese, Leiter, Levy, Lipska, Lundkvist, MacLeod, Mathieu, Meneghini, Onishi, Onishi, Philis-Tsimikas, Stratton, The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, UK Hypoglycaemia Study Group, UK Prospective Diabetes Study (UKPDS) Group, Vexiau, Waugh, World Medical Association, Zinman   +44 more
core   +1 more source

Flexibility in insulin prescription

Indian Journal of Endocrinology and Metabolism, 2016
This communication explores the concept of flexibility, a propos insulin preparations and insulin regimes used in the management of type 2 diabetes.
Sanjay Kalra, Yashdeep Gupta, Ambika Gopalakrishnan Unnikrishnan   +2 more
doaj   +1 more source